Ionis Pharmaceuticals, Inc. and ImmunityBio, Inc.: SG&A Spending Patterns Compared

Biotech Giants' SG&A Trends: Ionis vs. ImmunityBio

__timestampImmunityBio, Inc.Ionis Pharmaceuticals, Inc.
Wednesday, January 1, 2014432600020140000
Thursday, January 1, 201522620600037173000
Friday, January 1, 20169439100048616000
Sunday, January 1, 201753821000108488000
Monday, January 1, 201835463000244622000
Tuesday, January 1, 201946456000287000000
Wednesday, January 1, 202071318000354000000
Friday, January 1, 2021135256000186000000
Saturday, January 1, 2022102708000151000000
Sunday, January 1, 2023129620000232600000
Monday, January 1, 2024267474000
Loading chart...

Igniting the spark of knowledge

SG&A Spending Patterns: A Tale of Two Biotechs

In the dynamic world of biotechnology, understanding financial trends is crucial. Over the past decade, Ionis Pharmaceuticals, Inc. and ImmunityBio, Inc. have showcased distinct patterns in their Selling, General, and Administrative (SG&A) expenses. From 2014 to 2023, Ionis Pharmaceuticals consistently outpaced ImmunityBio in SG&A spending, peaking in 2020 with a 354% increase from 2014. Meanwhile, ImmunityBio's SG&A expenses saw a dramatic spike in 2015, surging by over 5000% compared to the previous year, before stabilizing. This divergence highlights Ionis's steady growth strategy versus ImmunityBio's initial aggressive expansion. As of 2023, Ionis's SG&A expenses were approximately 80% higher than ImmunityBio's, reflecting their differing operational focuses. These insights offer a window into the strategic priorities of these biotech giants, providing investors and analysts with valuable context for future financial decisions.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025